Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis
- 606 Downloads
In a retrospective study, 43 patients with dysplastic neoplasms of the bone marrow (myelodysplastic syndromes and myelodysplastic/myeloproliferative-overlap neoplasms) associated with marked (grades 2–3) fibrosis were examined. Histopathologic and morphologic findings as well as cytogenetic and molecular results were correlated with clinical endpoints. Multilineage dysplasia (34 of 43 patients, 79 %) and hypercellular bone marrow (64 %) were found in most patients. In ten of 35 patients, poor risk karyotypes according to the International Prognostic Scoring System (IPSS) were recorded. The JAK2 V617F mutation was detected in four of 30 patients (13 %), and the KIT D816V mutation was found in two of 30 patients (6 %). Patients were mainly treated with palliative drugs and best supportive care. After an observation time of 1–41 (median 21) months, ten of 43 patients (23 %) had developed a secondary acute leukemia. The median survival of all 43 patients was 21.4 months (range 1.8–88.2 months). Of all prognostic parameters examined, the blast cell count at diagnosis was found to be a most reliable and most predictive marker concerning survival and leukemia progression. This confirms previous studies in dysplastic bone marrow neoplasms without fibrosis.
KeywordsMyelodysplastic syndromes Chronic myelomonocytic leukemia Bone marrow fibrosis
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Brunning RD, Bennet JM, Flandrin G et al. (2001) Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 61–74Google Scholar
- 8.Marisavljevic D, Rolovic Z, Cemerikic V et al (2004) Myelofibrosis in primary myelodysplastic syndromes. Clin Biol Signif Med Oncol 21(4):325–331Google Scholar
- 11.Santos FPS, Schlette E, Kantarjian H et al. (2009) Myelodysplastic syndrome with fibrosis: experience of a single-institution with 139 patients. Blood 114 (24): Abstract 2775Google Scholar
- 13.Valent P, Orazi A, Büsche G, Schmitt-Gräff A, George TI, Sotlar K, Streubel B, Beham-Schmid C, Cerny-Reiterer S, Krieger O, Loosdrecht AVD, Kern W, Ogata K, Wimazal F, Csomor J, Varkonyi J, Sperr WR, Werner M, Kreipe H, Horny HP (2010) Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget 1:483–496PubMedGoogle Scholar
- 17.Brunning R, Orazi A, Germing U et al (2008) Myelodysplastic syndromes, chapter 5. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue, 4th edition. IARC, Lyon, pp 88–103Google Scholar
- 18.Greenberg P, Cox C, LeBeau M et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997(89):2079–2088Google Scholar
- 27.R Development Core Team, R Foundation for Statistical Computing (2009) R: a language and environment for statistical computing [Internet]. Vienna [cited 2009 Apr 17]. Available from: http://www.r-project.org/
- 28.Therneau TM, Lumley T (2009) Survival analysis, including penalised likelihood, original report by Thomas Lumley [Internet] [cited 2009 Apr 17]. Available from: http://www.r-project.org/
- 35.Haase D, Germing U, Schanz J, Pfeilstöcker M, Noesslinger T, Hildebrandt B, Kuendgen A, Luebbert M, Kunzmann R, Giagounidis AA, Aul C, Truemper L, Krieger O, Stauder R, Mueller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395PubMedCrossRefGoogle Scholar